Skip to main content
Have a personal or library account? Click to login
Overview of Chronic Rhinosinusitis with Nasal Polyps Cover

Overview of Chronic Rhinosinusitis with Nasal Polyps

Open Access
|Jun 2026

Abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease that remains a major challenge in otolaryngology. This review aims to summarize the current knowledge on CRSwNP and provide an overview of available treatment methods. We conducted a PubMed database search and identified 86 publications relevant to this paper.

CRSwNP is characterized by persistent sinonasal symptoms lasting more than 12 weeks (congestion, rhinorrhea, hyposmia) and bilateral polyps, confirmed by endoscopy or computed tomography showing inflammation. The estimated prevalence of CRSwNP ranges up to 4% in the general population and predominantly affects middle-aged patients. In most cases, CRSwNP is driven by a type 2 inflammatory response. Common comorbidities include asthma and aspirin-exacerbated respiratory disease.

Management follows a stepwise approach, and treatment selection depends on disease severity, previous treatment response, and type 2 biomarkers. Treatment typically begins with saline irrigation and intranasal corticosteroids. Refractory cases may require short courses of systemic steroids, endoscopic sinus surgery (ESS), or biologics (dupilumab, mepolizumab, omalizumab, and tezepelumab) targeting type 2 inflammation.

Future research should focus on improved phenotyping and cost-effectiveness.

DOI: https://doi.org/10.2478/bgbl-2026-0006 | Journal eISSN: 2956-6851 | Journal ISSN: 0373-174X
Language: English
Page range: 83 - 103
Submitted on: Apr 24, 2026
Accepted on: May 11, 2026
Published on: Jun 28, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2026 Radosław Jan Walkowski, Aleksandra Suchołbiak, Oskar Mikołajczyk, published by The Medical Library named after S. Konopka in Warsaw
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.